There are growing challenges to accurately predict drug-induced liver injury (DILI) risk tied to evolving immunotherapies and in patients with underlying chronic liver disease. This international academic-industry-government conference sponsored by the FDA and AASLD, will hear expert presentations on new treatments with hepatotoxic liability and discuss study populations of growing concern as well as many state-of-the-art scientific tools and methods that are now becoming available for the assessment of DILI risk. There will also be a robust exchange of ideas and debate towards establishing consensus among participants in the meeting as a prelude for a planned comprehensive revision of the seminal FDA guidance on the pre-marketing evaluation of DILI, issued 10 years ago.
Download the meeting syllabus [PDF].
Breakfast is served at 7 am ET both days.
Requests for cancellations must be submitted in writing to email@example.com.
Cancellations received on or before April 9, 2019 will be eligible for a full refund.
Cancellations received between April 10 – April 23, 2019 will be subject to a $50.00 cancellation fee.
Cancellations received on or after April 24, 2019 are not eligible for a refund.